Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept for anemia in adults with alpha-thalassemia HbH disease
2021-004928-15Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Aug 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alpha-thalassemia intermedia and anaemia comparing Luspatercept plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Erythroid response in transfusion-dependent participants. Started Aug 2022; status: active.
02
Drugs
luspatercept
03
Conditions
alpha-thalassemia intermediaanaemia
Beyond the preview
Go deeper on 2021-004928-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004928-15.